Merck Collaborates with OncoSec to Evaluate TAVO (tavokinogene telseplasmid) + Keytruda (pembrolizumab) in P-III KEYNOTE-C87 Trial for Late-Stage Metastatic Melanoma

Shots:

• The companies collaborated to evaluate OncoSec’s TAVO + Merck’s Keytruda vs SoC in a P-III KEYNOTE-C87 trial in ~400 patients with metastatic melanoma who are refractory to immune checkpoint therapy across the US, Canada, EU & Australia
• The companies will responsible for internal costs with OncoSec covering the third-party costs. The trial is intended to support accelerated approval or a full licensure of the combination in the US
• TAVO demonstrated a local & systemic anti-tumor response in several clinical trials, including the P-IIb KEYNOTE-695 trial for metastatic melanoma & P-II KEYNOTE-890 trial for TNBC

Click here to read full press release/ article | Ref: PR Newswire | Image: PR Newswire